Floatz logo

XENON

Subarachnoid Hemorrhage, Aneurysmal

Turku University HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Subarachnoid Hemorrhage, Aneurysmal cohort.

Asset / SponsorPhaseRating
S-Ketamine
Rigshospitalet, Denmark
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Jenna L Leclerc MD, PhD
Phase 2/3B
(-)-OSU 6162
Oslo University Hospital
Phase 2B
PROPOFOL
Jenna L Leclerc MD, PhD
Phase 2/3B
Erythropoietin Beta
University of Cambridge
Phase 2B
Oxygen
Turku University Hospital
Phase 2CCC
AIR
Turku University Hospital
Phase 2CCC

Same molecule, other indications

XENON is also rated in:

cystic fibrosisDormant
BB
Indicative ·
65 / 100
View asset →
asthmaDormant
B
Indicative ·
63 / 100
View asset →
pulmonary fibrosisDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →